Stabilization of red blood cell membranes by thalidomide in vitro

Immunopharmacology and Immunotoxicology

Volumn 26, Issue 4, 2004, Pages 501-509

  Tadesse, Azeb ^a,b   Sandoval, Felipe ^b   Shannon, E J ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Cell membranes; Neutrophils; RBC; Thalidomide

Indexed keywords

LACTATE DEHYDROGENASE; PLACEBO; THALIDOMIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ERYTHROCYTE; ERYTHROCYTE FRAGILITY; ERYTHROCYTE MEMBRANE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; MEMBRANE STABILIZATION; MONOCYTE; NEUTROPHIL; NORMAL HUMAN; OSMOTIC FRAGILITY; PRIORITY JOURNAL;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; CELL MEMBRANE; ERYTHROCYTE MEMBRANE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MONOCYTES; NEUTROPHILS; OSMOTIC FRAGILITY; REACTIVE OXYGEN SPECIES; THALIDOMIDE;

EID: 11344290078     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.1081/IPH-200042279     Document Type: Article

References (18)

1. Zwingenberger, K.; Wnendt, S. Immunomodulation by thalidomide: systematic review of the literature and of unpublished observations. J. Inflam. 1996, 46, 177-211.
2. Tseng, S.; Pak, G.; Washenik, K.; Pomeranz, M.K.; Shupack, J.L. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J. Am. Acad. Dermatol. 1996, 35, 969-979.
3. Mabalay, M.C.; Helwig, E.B.; Tolentino, J.G.; Binford, C.H. The histopathology and histochemistry of erythema nodosum leprosum. Int. J. Lepr. 1964, 33 (1), 28-49.
4. Burns, R.A.; Davis, W.J. Recurrent apthous stomatitis. Am. Fam. Phys. 1985, 32 (2), 99-104.
5. Parham, P. The Body's defense against infection. In The Immune System; Garland Publishing/Elsevier Science Ltd, 2000; 210-211.
6. Hastings, R.C.; Morales, M.J.; Shannon, E.J. Studies on the mechanism of action of thalidomide in leprosy. Pharmacologist 1976, 18, 218-223.
7. Dacie, J.V.; Lewis, S.M. Mannual procedures in hematology and coagulation. In Practical Hematology, 5th Ed.; Churchill-Livingstone: New York, 1975; 337-338.
8. Shannon, E.J.; Sandoval, F.; Krahenbuhl, J.L. Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-α. Immunopharmacology 1997, 36, 9-15.
9. Penninck, F.; Cheng, N.; Kerrernans, R.; Van Damme, B.; De Loecker, W. The effects of different concentrations of glycerol and dimethylsulfoxide on the metabolic activities of kidney slices. Cryobiology 1983, 20, 51-60.
10. Preparation and functional analysis of human nonlymphoid cells. In Current Protocol in Immunology; John Wiley & Sons, 2003.
11. Shannon, E.J.; Howe, R.C.; McLean, K.; Hastings, R.C. Thalidomide does not perturb CD2, CD4, CD5, CD8, HLA-DR, or HLA-A, B, C molecules in vitro on the memebranes of cells with immune potential. Immunopharmacol. Immunotoxicol. 1994, 16(4), 717-729.
12. Barnhill, R.L.; Doll, N.J.; Millikan, L.E.; Hastings, R.C. Studies on the antiinflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J. Am. Acad. Dermatol. 1984, 11, 814-819.
13. Golhman-Yahr, M.; Convit, J.; Rodriguez-Ocoa, G.; Aranzazu, N.; Villalba-Pimentel, L.; Ocanto, A.; De Gomez, M.E. Significance of neutrophils activation in reactional lepromatous leprosy: effects of thalidomide in vivo and in vitro. Activation in adjuvant disease. Int. Arch. Allergy Appl. Immunol. 1978, 57, 317-332.
14. Hastings, R.C.; Morales, M.J. The effect of thalidomide on neutrophil function. Int. J. Lepr. 1978, 46, 120.
15. Wiles, M.E.; Dykens, J.A.; Wright, C.D. Regulation of polymorphonuclear leukocyte membrane fluidity: effect of cytoskeletal modification. J. Leukoc. Biol. 1994, 56, 192-199.
16. Anderson, R.; Theron, A.J.; Feldman, C. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation 1996, 20 (6), 693-705.
17. Ericksson, T. Pharmacokinetics of the Enantiomers of Thalidomide. Doctoral Dissertation, Department of Clinical Pharmacology, Lund University, S-221 85 Lund, Sweden, 1997.
18. Theron, A.J.; Feldman, C.; Anderson, R. Investigation of the anti-inflammatory and membrane-stabilizng potential of spiramycin in vitro. J. Antimicrob. Chemother. 2000, 46, 269-271.